南非高HIV负担农村地区全口服含贝达喹啉短程方案治疗耐利福平结核的安全性与有效性
该回顾性队列分析评估了南非夸祖鲁-纳塔尔农村地区117例耐利福平结核患者使用含贝达喹啉和利奈唑胺的全口服9-12个月短程方案的安全性与有效性。结果显示治疗成功率为75.2%,培养转阴中位时间56天,死亡率为12.8%,贫血是最常见的严重不良事件,利奈唑胺中断率为25.2%。结论认为该方案在高HIV负担农村环境下效果良好,但不良事件常见,需加强监测管理。
要点
- 含贝达喹啉和利奈唑胺的全口服短程方案治疗RR-TB治疗成功率达75.2%。
- 贫血是最常见严重不良事件,中位发生时间7.1周,利奈唑胺中断率25.2%。
- 高HIV合并率(68.4%)背景下该方案仍显示良好结局,但需加强不良事件监测。
核心结论
- 含贝达喹啉和利奈唑胺的全口服短程方案在高HIV负担农村地区治疗RR-TB显示良好结局。
- 不良事件常见,尤其与利奈唑胺相关,但在项目条件下可管理。
研究设计与样本
- 回顾性队列分析,纳入2018年7月1日至2019年4月30日在King Cetshwayo District 3家机构接受标准化全口服短程方案治疗的RR-TB患者,共117例。
- 数据来源为电子登记系统(EDR web)和机构临床病历,录入Epi-Info数据库。
主要发现
- 117例患者中68.4%(95%CI:59.3-76.3)HIV检测阳性。
- 培养转阴中位时间56天(95%CI:50-57)。
- 治疗成功率为75.2%(95%CI:66.5-82.3)。
- 队列内死亡率为12.8%(95%CI:7.8-20.3)。
- 贫血是最常见的严重不良事件,发生严重贫血的中位时间为治疗开始后7.1周(IQR 4.0-12.9);利奈唑胺中断率为25.2%(95%CI:17.8-34.5)。
临床怎么用
- 在高HIV负担资源有限地区,可考虑使用含贝达喹啉和利奈唑胺的全口服短程方案治疗RR-TB。
- 引入新方案时需培训 staff 监测、管理和报告不良事件,尤其关注利奈唑胺相关贫血。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: At the end of 2018, South Africa updated its all-oral regimen, to include bedaquiline (BDQ) and 2 months of linezolid (LZD) for all patients initiating the shorter 9-12 months regimen for rifampicin-resistant tuberculosis (RR-TB). We assessed a group of patients in rural KwaZulu-Natal for safety and effectiveness of this treatment regimen under programmatic conditions. METHODS: We conducted a retrospective cohort analysis on RR-TB patients treated with a standardized all-oral short regimen between 1 July 2018 and 30 April 2019 in 3 facilities in King Cetshwayo District. An electronic register (EDR web) and facility-based clinical charts were used to collect variables, which were entered into an Epi-Info database. RESULTS: Our cohort included 117 patients; 68.4% (95% confidence interval [CI]: 59.3-76.3) tested positive for human immunodeficiency virus (HIV). The median time to culture conversion was 56 days (95% CI: 50-57). Treatment success was achieved in 75.2% (95% CI: 66.5-82.3) of patients. Mortality within the cohort was 12.8% (95% CI: 7.8-20.3). Anemia was the most frequent severe adverse event (AE). The median time to develop severe anemia was 7.1 weeks (interquartile range [IQR] 4.0-12.9) after treatment initiation. LZD was interrupted in 25.2% (95% CI: 17.8-34.5) of participants. CONCLUSIONS: An all-oral shorter regimen, including BDQ and LZD as core drugs for the treatment of RR-TB, shows good outcomes, in a high HIV burden rural setting. AEs are common, especially for LZD, but could be managed in the program setting. Support is needed when introducing new regimens to train staff in the monitoring, management, and reporting of AEs.
引用
- Tack I, Dumicho A, Ohler L, et al. Safety and Effectiveness of an All-Oral, Bedaquiline-Based, Shorter Treatment Regimen for Rifampicin-Resistant Tuberculosis in High Human Immunodeficiency Virus (HIV) Burden Rural South Africa: A Retrospective Cohort Analysis. Clin Infect Dis. 2021. PMID: 33372989. doi:10.1093/cid/ciaa1894
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。